Figure 1 Stacked donut charts depicting reasons for GLP-1RA therapy discontinuation stratified by lines of therapy (A), and contribution of specific agent to the 3 categories of discontinuation reasons (B) GLP-1, glucagon-like peptide 1 With respect to specific agents, the treatment-related reasons for discontinuation were reported most frequently with liraglutide (50%), followed by dulaglutide (32%), and semaglutide (18%)
The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype
Mostafa, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
What if Ive lost a significant amount of weight on my own
When you stop using the spray, your bodys production of melanin will slow, and your tan will fade